Pharos received the GMP certification for the production facility of Pharos Malta (Pharos MT). Pharos MT’s facility is located in Hal Far manufacturing site and has the capacity to produce 1.5 billion tablets per annum. Pharos acquired the facility in May 2018 from Teva in an effort to transition from a purely development to a development & manufacturing organisation.
The new facility improves Pharos’ market positioning in terms of increased capabilities, increased R&D flexibility and lower reliance to third parties.